Gwenn Hansen - 05 Aug 2026 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Reporting relationship: Chief Scientific Officer
Issuer ticker: NRIX
Reported as of: 05 Aug 2026
Net transaction value: -$108,900
SEC form: 4
Accepted by SEC: 05 Aug 2026, 18:59:04 UTC
Prior SEC filing: 05 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen

Key filing fact

Gwenn Hansen filed Form 4 for Nurix Therapeutics, Inc. (NRIX) on 05 Aug 2026.

Key facts

This page summarizes Gwenn Hansen's Form 4 filing for Nurix Therapeutics, Inc. (NRIX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Aug 2026, 18:59.

Change

Previous filing in this sequence was filed on 05 Aug 2026.
Current net transaction value: -$108,900.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001817160 Primary reporting owner

Hansen Gwenn

Relationship: Chief Scientific Officer
Address: C/O NURIX THERAPEUTICS, INC., 1600 SIERRA POINT PKWY, BRISBANE
Signature: /s/ Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen
Signature date: 05 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NRIX transaction

Common Stock

Options Exercise

Transaction value
Shares: +4,356
Change %: +3.7%
Price: $1.86^*
Shares after: 121,583
Date: 05 Aug 2026
Ownership: Direct
Footnotes: F1

NRIX transaction

Common Stock

Sale

Transaction value: $108,900
Shares: -4,356
Change %: -3.6%
Price: $25.00
Shares after: 117,227
Date: 05 Aug 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NRIX transaction Derivative

Employee Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -4,356
Change %: -6.5%
Price: $0.000000^*
Shares after: 62,310
Date: 05 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,356
Exercise price: $1.86
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Footnote F2

The stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023.